CorNeat Vision has announced the U.S. launch of the CorNeat EverPatch, the first-ever synthetic tissue substitute for use in glaucoma shunt and ocular surface surgeries.
Refresh me on this company.
The Israel-based CorNeat Vision is a clinical-stage medical device company with a product portfolio of biomimetic medical implants and technology.
Its core technology is the CorNeat EverMatrix, a patented, core tissue-integrating material platform that is currently the only synthetic non-degradable patch material in ocular surgery (more on that in a moment).
The company’s product lineup also includes:
- CorNeat gPatch (for permanent periodontal regeneration membrane)
- CorNeat KPro (for artificial cornea)
- CorNeat eShunt (a glaucoma drainage device).
Explain this core technology …
The EverMatrix is designed to displace (replace) the use of tissue and degradable biological scaffolds that are used in surgical procedures in various fields of medicine.
It can also be produced in 2D and 3D forms, allowing for:
- Physical attachment of implants to tissue
- Implant concealment
- Soft tissue repair and permanent reinforcement
- Membrane and tissue barrier fabrication
Gotcha. Now talk about the EverPatch.
The CorNeat EverPatch is the first-of-its-kind inert, synthetic, and non-degradable tissue.
Its purpose: to displace the use of donor and processed tissue often used in ocular surgeries.
The scleral patch is made of a non-woven, polymer matrix (the EverMatrix) that combines with surrounding tissue in order to support the scleral and assist in reconstructing the ocular surface.
Note: this device is the first of CorNeat’s products to incorporate the EverMatrix technology.
Is it FDA-cleared?
It is! The patch was granted 510(k) clearance in June 2023. Read our coverage here.
Talk details about this.
Per CorNeat, the scleral patch is:
- Long-lasting material
- Bio-mechanical integration with a minor and progressively subsiding inflammatory response
- Easy to handle and suture
- Elasticity and durableness prevent suture-caused tears
- Synthetic tissue for preventing disease transmission
- Biocompatible and thin (100 μm)
- Minimizes risk of corneal dellen
- Biocompatible and thin (100 μm)
- Cost-effective
- Intended to reduce operating time and eye bank costs by eliminating steps of transportation and storage of biological materials
- Longer shelf life than organic/degradable solutions
- Available as an off-the-shelf device
- Aesthetically pleasing
- Translucent when wet; nearly invisible once implanted subconjunctivally
Interesting. So how is the Everpatch different from other patch tissue?
Gilad Litvin, MD, CorNeat Vision’s CMO and co-founder, previously stated that the ophthalmic patch:
- Is significantly thinner than processed patch tissue ( 100 μm vs 300 to 450 μm, as noted above)
- Provides better handling
- Contains holes that enable accurate positioning and anchoring
- Facilitate direct conjunctival adhesion to the scleral
What else does the company have to say about it?
“Its novel structure enables seamless integration with surrounding tissue without triggering a chronic foreign body response,” the company stated.
Further, CorNeat noted that the patch is designed to provide a new, optimal solution for reinforcing tissue over glaucoma drainage devices by “addressing complications such as tube exposure that often require reoperation.”
So where can I find it?
Per CorNeat Vision, the EverPatch is now available across the U.S. (and select countries). As an added bonus, the patch will be showcased at the following 2024 annual conferences in the near future:
- American Glaucoma Society (AGS)Feb. 29 - March 3 (Huntington Beach, California)
- American Society of Cataract and Refractive Surgery (ASCRS) April 5-8 (Boston, Massachusetts)